Last updated on December 2019

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies


Brief description of study

This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of AB154 as monotherapy and in combination with AB122 in participants with advanced solid malignancies.

Detailed Study Description

This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of AB154 as monotherapy and in combination with AB122 in participants with advanced solid malignancies. In this dose escalation study, participants will receive AB154 administered intravenously as monotherapy or in combination with AB122. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for study drug discontinuation occurs.

Clinical Study Identifier: NCT03628677

Find a site near you

Start Over

Huntersville, NC

Huntersville, NC United States
  Connect »

Principal Investigator

San Antonio, TX United States
  Connect »

Spokane, WA

Spokane, WA United States
  Connect »

Darlinghurst, Australia

Darlinghurst, Australia
  Connect »

Heidelberg, Australia

Heidelberg, Australia
  Connect »

Principal Investigator

Los Angeles, CA United States
  Connect »

Principal Investigator

South Brisbane, Australia
  Connect »